Clinical Trial Update: Efficacy and Safety Study of a Modified SOX Regimen in First-Line Treatment of Unresectable Gastric Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial assessing efficacy and safety of a modified S-1 plus oxaliplatin (SOX) regimen as first-line treatment for unresectable gastric adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma

Drugs mentioned

• OXALIPLATIN (Oxaliplatin)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University | Conditions: Gastric Adenocarcinoma | Phase 2 | Status: UNKNOWN